The international journal of neuropsychopharmacology
Pharmacokinetic and pharmacodynamic results from a randomized controlled study with the GHSR blocker PF-5190457 in recently abstinent patients with alcohol use disorder.
Ryan E Tyler, Rabea K Pfaff, R M Naseer Khan, Anna Loften, Ryan Zurick, Yi Zeng, Oluwatobi T Arisa, Charlotte Harvey, Fatemeh Akhlaghi, William D Figg, Mehdi Farokhnia, Lorenzo Leggio
Published: 202510.1093/ijnp/pyaf081
Abstract
OBJECTIVE: Ghrelin and LEAP2 act via the growth hormone secretagogue receptor (GHSR), which modulates feeding, alcohol use, and endocrine and immune system function. The GHSR blocker PF-5190457 has potential as a novel pharmacotherapy for alcohol use…
Preview only. Read the full abstract at the source